Randomized phase II adjuvant trial to compare two treatment durations of icotinib (2 years versus 1 year) for stage II-IIIA EGFR-positive lung adenocarcinoma patients (ICOMPARE study)

C. Lv,R. Wang,S. Li,S. Yan,Y. Wang, J. Chen,L. Wang,Y. Liu, Z. Guo, J. Wang, Y. Pei, L. Yu,N. Wu,F. Lu, F. Gao, J. Chen,Y. Liu,X. Wang,S. Li, B. Han

ESMO Open（2023）

引用 2|浏览5

暂无评分

摘要

•Two-year adjuvant icotinib had a significantly prolonged DFS compared with 1-year treatment in stage II-IIIA NSCLC.•PFS benefit translated into a significant OS benefit, possibly due to the longer duration of adjuvant targeted therapy.•Safety outcomes were similar in both groups.

查看译文

关键词

non-small-cell lung cancer, adjuvant targeted therapy, EGFR mutations, icotinib, disease-free survival

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要